Investeringsforeningen Sparinvest suspenderer handel med alle afdelinger
Under henvisning til Nasdaq Copenhagens regler for udstedere af investeringsbeviser skal ID-Sparinvest, Filial af Sparinvest S.A., Luxembourg hermed på vegne af de berørte afdelinger i Investeringsforeningen Sparinvest offentliggøre, at indberetning af indre værdier til Nasdaq Copenhagen er udeblevet grundet tekniske udfordringer. Handel med de berørte afdelinger ønskes derfor midlertidigt suspenderet.
Der er tale om følgende afdelinger:
| Orderbookcode | Afdelingsnavn | ISIN |
| SPIKOOKLA | Sparinv Korte Obligationer KL A | DK0060105203 |
| SPIMLOKLA | Sparinv Mellemlange Obligationer KL A | DK0060105476 |
| SPILOLKLA | Sparinv Lange Obligationer KL A | DK0060105393 |
| SPINOBKLA | Sparinv Nye Obligationsmarkeder KL A | DK0016030786 |
| SPIVIGKLA | SparInvest Virksomhedsobligationer IG A | DK0060444255 |
| SPISOKLA | Sparindex INDEX Stabile Obl. KL A | DK0060057487 |
| SPIVHYKORTKLA | Sparinv Virksomhedsobligationer HY KortA | DK0060530764 |
| SPIVHYKLA | SparInvest Virksomhedsobligationer HY A | DK0060819324 |
| SPIMAKLA | Sparinvest Mix Aktier KL A | DK0010014778 |
| SPIVAKLA | Sparinv Value Aktier KL A | DK0010079631 |
| SPIVEUKLA | Sparinv Value Europa KL A | DK0060032571 |
| SPIVEMKLA | Sparinv Value Emerging Markets KL A | DK0010304856 |
| SPIBDAAKKKLA | Sparinvest Bæredygtige Aktier Akk. KL A | DK0060012896 |
| SPIDKAKLA | Sparinv Danske Aktier KL A | DK0010068006 |
| SPIDJWKL | Sparindex INDEX DJSI World KL | DK0010297464 |
| SPIEMIKL | Sparindex INDEX Emerging Markets KL | DK0060300762 |
| SPIEUGKL | Sparindex INDEX Europa Growth KL | DK0010297548 |
| SPIEUCKL | Sparindex INDEX Europa Small Cap KL | DK0010297621 |
| SPIEUVKL | Sparindex INDEX Europa Value KL | DK0010297704 |
| SPIGLAMRIKL | Sparindex INDEX Globale Akt Min Risk KL | DK0060031847 |
| SPIBJAKL | Sparindex INDEX Bæredygtige Japan KL | DK0010297977 |
| SPIC25KL | Sparindex INDEX OMX C25 KL | DK0060442556 |
| SPIUSGKL | Sparindex INDEX USA Growth KL | DK0010298272 |
| SPIUSSKL | Sparindex INDEX USA Small Cap KL | DK0010298355 |
| SPIUSVKL | Sparindex INDEX USA Value KL | DK0010298439 |
| SPIBDA | Sparinvest Bæredygtige Aktier KL A | DK0061294048 |
| SPIGFA | Sparinvest Globale Fokusaktier KL A | DK0061293826 |
| SPIMRA | Sparinvest Mix Rente KL A | DK0061551702 |
| SPIMMRIA | Sparinvest Mix Maksimum Risiko KL A | DK0061551892 |
| SPIBDVAA | Sparinvest Bæredygtige Value Aktier KL A | DK0061551546 |
| SPIMLRKLA | Sparinv Mix Lav Risiko KL A | DK0060623189 |
| SPIMMRKLA | Sparinv Mix Mellem Risiko KL A | DK0060623262 |
| SPIMHRKLA | Sparinv Mix Høj Risiko KL A | DK0060623346 |
| SPIMIXMINRISKKLA | Sparinvest Mix Minimum Risiko KL A | DK0060914901 |
Vi beklager forsinkelsen.
Henvendelser vedrørende nærværende fondsbørsmeddelelse kan rettes til npa.pm@nykredit.dk cc jna@nykredit.dk
Med venlig hilsen
Dirk Schulze
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
NATALEE (TRIO033) Phase III trial demonstrates ribociclib significantly reduces the risk of recurrence for patients with early breast cancer, at interim analysis27.3.2023 15:28:42 CEST | Press release
EDMONTON, Alberta, March 27, 2023 (GLOBE NEWSWIRE) -- Translational Research In Oncology (TRIO) today announced positive topline results from NATALEE (TRIO033), a Novartis sponsored Phase III trial of ribociclib plus endocrine therapy (ET) as adjuvant treatment for patients with stages II and III early breast cancer (EBC) at risk of disease recurrence. NATALEE (TRIO033) met its primary endpoint at a pre-planned interim analysis, achieving a statistically significant improvement in invasive disease-free survival (iDFS) in women and men with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) EBC, when compared to ET alone. “At TRIO, we always strive to improve the lives of cancer patients by conducting clinical trials that might make a fundamental difference in outcomes. We are very proud of our collaboration with Novartis in the conduct of the NATALEE (TRIO033) trial. The results announced today are a significant step forward towards reducing the ris
Sbanken ASA: Tap Issue ISIN NO001108758727.3.2023 15:19:31 CEST | Press release
Tap Issue Sbanken ASA 21/25 FRN C, ISIN NO0011087587 amount NOK 800.000.000,-. New outstanding amount NOK 3.500.000.000,- This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
Sbanken ASA: Utvidelse av ISIN NO001108758727.3.2023 15:19:31 CEST | Pressemelding
Utvidelse av Sbanken ASA 21/25 FRN C, ISIN NO0011087587 beløp NOK 800.000.000,- Nytt utestående volum NOK 3.500.000.000,- Denne opplysningen er informasjonspliktig etter verdipapirhandelloven §5-12
AIM ImmunoTech to Report Full Year 2022 Financial Results on March 31, 2023 and Host Inaugural Quarterly Conference Call and Webcast27.3.2023 15:05:00 CEST | Press release
OCALA, Fla., March 27, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases — including COVID-19, the disease caused by the SARS-CoV-2 virus — today announced that it will report its financial results for the full year December 31, 2022 after market close on Friday, March 31, 2023. AIM ImmunoTech management will host its inaugural quarterly conference call and live audio webcast to discuss the operational and financial results on Monday, April 3rd at 8:30 AM ET. The call will be hosted by members of AIM’s leadership team, Thomas K. Equels, Chief Executive Officer and Christopher McAleer, PhD, Scientific Officer. Interested participants and investors may access the conference call by dialing (877) 407-9219 (domestic) or (201) 689-8852 (international) and referencing the AIM ImmunoTech Conference C
Transactions in connection with share buy-back program27.3.2023 15:00:41 CEST | Press release
Company Announcement COPENHAGEN, Denmark; March 27, 2023 –Genmab A/S (Nasdaq: GMAB). On February 22, 2023, Genmab announced the initiation of a share buy-back program to honor our commitments under our Restricted Stock Units program. The share buy-back program is expected to be completed no later than March 31, 2023, and comprises up to 220,000 shares. The following transactions were executed under the program from March 20, 2023, to March 24, 2023: No. of sharesAverage price (DKK)Total value (DKK)Accumulated through last announcement167,000427,631,620March 20, 20236,0002,504.2415,025,440March 21, 20235,000 2,541.7712,708,850March 22,20235,0002,541.4412,707,200March 23, 20237,0002,529.9917,709,930March 24, 20237,0002,564.9117,954,370Total30,00076,105,790Accumulated under the program197,000503,737,410 Details of each transaction are included as an appendix to this announcement. Following these transactions, Genmab holds 740,416 shares as treasury shares, corresponding to 1.12% of the to